托法替尼治疗溃疡性结肠炎的研究进展

Research progress of Tofacinib in the treatment of ulcerative colitis

托法替尼作为一种新型的JAK激酶抑制剂,主要通过抑制JAK/STAT通道来抑制溃疡性结肠炎(ulcerative colitis,UC)的发生和发展。目前已有多项研究证明托法替尼对于UC的治疗疗效显著,可以极大地改善患者的症状、提高患者生活质量。本文主要从疾病背景、发病机制、药物动力学、临床试验数据、不良反应等多方面进行概述,以期为临床决策提供参考。

As a new JAK kinase inhibitor,Tofacinib can inhibit the occurrence and development of ulcerative colitis(UC)by inhibiting JAK/STAT pathway.At present,a number of studies have proved that the therapeutic effect of Tofacinib on UC is significant,which can greatly improve the symptoms of patients and improve the quality of one's life.In this paper,the disease background,pathogenesis,pharmacokinetics,clinical trial data,adverse reactions and other aspects were summarized in order to provide reference for clinical decision-making.